Demand for restrictive cardiomyopathy treatment will increase through 2036, with restrictive cardiomyopathy at 36% of the type segment in 2026. The market was valued at USD 112.3 million in 2025 and is expected to reach USD 206.64 million by 2036, creating an incremental opportunity of USD 87.94 million.